- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
With increasing global use of antiretroviral therapy (ART) to both treat and prevent HIV, and increasing global trends in HIV drug resistance ( HIVDR), efforts to improve HIV programme quality and prevent the emergence and transmission of drug-resistant HIV must be strengthened.
This global report is based on 59 countries that reported data from more than 12 000 clinics from cohorts of patients receiving ART between 2004 and 2014. The report includes the most recent clinic-level data reported to WHO in 2015 –2016 and reflects a lag due to the 12 month cohort reporting period.
The Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive (Global Plan) was launched in June 2011. It prioritizes the 22 countries1 that, in 2009, accounted for 90% of the global number of pregnant women living with HIV who were in need of services to prevent mother-to-child transmission of HIV. This report summarizes the history and development of the Global Plan, its achievements in reaching ambitious goals, lessons learned and directions for future progress to end new HIV infections among children.
Keywords: HIV, infections, children, prevention, antiretroviral medicines, pregnant women, breastfeeding
See Regional Progress Hepatitis B Vaccination Coverage, 1990—2015, Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children
The 10th Asia-Pacific United Nations Prevention of Parent-To-Child Transmission (PPTCT) of HIV and Syphilis Task Force meeting was held from 15 to 17 September 2015 in Beijing, China. More than 230 participants from 19 Asia-Pacific countries, including 90 participants from provinces in China, as well as civil society and United Nations partners attended the meeting. The meeting focused on steps towards achieving and validating the elimination of parent-to-child transmission (EPTCT) of infectious diseases, and the integration of services to contribute to improving maternal and child health (MCH) outcomes.
Communicable diseases such as HIV, TB and malaria remain among the leading causes of illness, death and impoverishment in our region, and infection levels continue to rise in many settings and populations. Unless focused efforts are undertaken to build on the gains to date, communities that remain vulnerable to neglected tropical diseases such as leprosy, kala-azar and filariasis will continue to be left behind. This report focuses on the historic opportunity for the WHO South-East Asia Region to end the scourge of communicable diseases for good.
Keywords: HIV, TB, malaria, neglected tropical diseases, public health
The objective of this guideline is to provide a framework for the treatment of Filipino HIV patients using an evidence-based approach, with emphasis on locally available treatment. The target audience is not only the infectious diseases subspecialist who treats HIV but also internists, family physicians, pulmonary specialists and other subspecialists who are taking care of or who wish to care for persons living with HIV.
Syphilis, a sexually transmitted bacterial infection, affects almost 40 million people worldwide. Like HIV, it can be passed from a pregnant woman to her unborn child. In pregnancy, if untreated, syphilis can result in severe outcomes for mother and infant. Yet, transmission can be effectively prevented with inexpensive and easily available penicillin treatment for pregnant women.6 Recognizing the opportunity to test and treat mothers and babies during antenatal or perinatal care, in 2007, the WHO and its partners published the Global elimination of congenital syphilis: rationale and strategy for action. The goal was to increase the number of pregnant women tested for syphilis to 90 per cent and to provide adequate treatment to at least 90 per cent of seropositive pregnant women by 2015.
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome. It also provides information on the production of new hepatitis C drugs and generic versions worldwide, including where the drugs are registered, where the drugs are patented and where not, and what opportunities countries have under the license agreements that were signed by some companies as well as current pricing of all recommended DAAs, including by generic companies all over the world.
Keywords: HIV, hepatitis C, HCV, treatment, diagnosis, testing
Greatly expanded access to routine viral load testing will be a game-changer in the global response to AIDS. Routine viral load tests improve treatment quality and individual health outcomes for people living with HIV, contribute to prevention, and potentially reduce resource needs for costly second- and third-line HIV medicines.
In 2013, viral hepatitis was a leading cause of death worldwide (1.46 million deaths, a toll higher than that from HIV, tuberculosis or malaria, and on the increase since 1990). More than 90% of this burden is due to the sequelae of infections with the hepatitis B virus (HBV) and hepatitis C virus (HCV).
Prevention can reduce the rate of new infections, but the number of those already infected would remain high for a generation. In the absence of additional efforts, 19 million hepatitis-related deaths are anticipated from 2015 to 2030. Treatment now can prevent deaths in the short- and medium term.